Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

In a way, the requiem of the now-dismantled agency can be told through its people — including some entire families, like the ...

People taking Eli Lilly and Co.'s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the medications.

President Donald Trump on Sunday said he will sign an executive order to slash prescription-drug prices.

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

The president is planning Monday to revive a plan from his first term, which would peg the prices the United States pays for ...

A group of 49 white South Africans departed their homeland Sunday for the United States on a private charter plane having ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. Lilly ...